Allife Medical Science

Beijing Allife Medical Science and Technology is a clinical-stage biotechnology company based in Beijing, China, dedicated to the development of innovative cell-based therapies. The company's primary focus lies in chimeric antigen receptor T-cell (CAR-T) therapies for hematological malignancies and regenerative medicine applications using stem cell technology. Allife's pipeline includes candidates targeting CD19 and BCMA for the treatment of B-cell lymphoma and multiple myeloma. Additionally, the company is exploring universal CAR-T (UCAR-T) platforms to improve the accessibility and scalability of cell therapies. Through its research and development efforts, Allife seeks to address significant unmet medical needs in oncology and regenerative medicine.